New Weight-Loss drug MD-18 enters early human safety testing
NCT ID NCT06739707
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial is testing a new drug called MD-18 in healthy adults who are overweight or obese. The main goal is to check if the drug is safe and how the body processes it. About 54 participants will receive either MD-18 or a placebo by injection. The study is currently on hold.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- MD-18
- What this could lead to
- If successful, this could point toward a new treatment to help control weight in people who are overweight or obese.
- What could go wrong
- This is a very early Phase 1 trial focused on safety, not weight loss. It is currently suspended, and the drug may not work or could have side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sheba Medical Center
Ramat Gan, Please Select, 522651, Israel
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new stomach and gut bypass surgery tackle obesity and diabetes?
- Can a Two-Drug combo tip the scales against obesity?
- Can Weight-Loss surgery change how medications work?
- Coffee grounds probiotic could reshape gut health and fight inflammation
- Can shedding pounds reboot the Heart's exercise engine?
- Can stomach surgery alter how painkillers work?